The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Novel agents vs. standard chemotherapy for first-line salvage treatment following CAR-T in LBCL
Gloria Iacoboni, MD, Vall d’Hebron University Hospital, Barcelona, Spain, presents results from a retrospective multicenter study assessing first-line salvage treatments for patients with large B-cell lymphoma (LBCL) progressing after CAR-T therapy. Four salvage treatments were used, including standard chemotherapy (CT), rituximab-polatuzumab-bendamustine (POLA), bispecific antibodies (BiTEs) and immune checkpoint inhibitors (ICIs). The study demonstrated that salvage therapy with polatuzumab-containing regimens and bispecific antibodies yielded higher response rates and improved progression-free survival (PFS). To conclude, Dr Iacoboni comments on the importance of considering potential toxicities associated with these treatment approaches. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
